Small specialty pharma Trimeris
Unfortunately for Trimeris, Fuzeon is only approved as a treatment for patients failing other HIV drugs like Abbott Labs'
Fortunately for Trimeris, all the Fuzeon sales declines in the past six months have occurred in the U.S. and Canada. In the rest of the world, sales by partner Roche grew 13% year over year in Q4. But U.S. sales are falling more quickly than foreign sales are growing, and it won't take long for Fuzeon's competitors to reach other countries as well.
Is Trimeris a cash flow-positive, cigar-butt value pick, as some investors consider fellow pharma QLT
Is Trimeris a value or value trap? See what other investors think, and share your own opinions, on Motley Fool CAPS.